These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39391325)

  • 1. A Review of the Potential Role of Sotagliflozin: A Dual SGLT2 and SGLT1 Inhibitor-in the Treatment of Heart Failure.
    Tran BAC; White RT; Bullers K; Cornelio CK
    J Pharm Technol; 2024 Oct; 40(5):248-256. PubMed ID: 39391325
    [No Abstract]   [Full Text] [Related]  

  • 2. Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure.
    Long A; Salvo M
    Ann Pharmacother; 2024 Sep; 58(9):935-946. PubMed ID: 38014844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
    Bhatt AS; Bhatt DL; Steg PG; Szarek M; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Testani JM; Wilcox CS; Davies M; Pitt B; Kosiborod MN
    J Am Coll Cardiol; 2024 Sep; 84(12):1078-1088. PubMed ID: 39260929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
    Koufakis T; Mustafa OG; Tsimihodimos V; Ajjan RA; Kotsa K
    Drugs; 2021 Aug; 81(12):1365-1371. PubMed ID: 34232488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality.
    Iyer N; Hussein S; Singareddy S; Sn VP; Jaramillo AP; Yasir M; Nath TS
    Cureus; 2023 Sep; 15(9):e45525. PubMed ID: 37868384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
    Aggarwal R; Bhatt DL; Szarek M; Cannon CP; McGuire DK; Inzucchi SE; Lopes RD; Davies MJ; Banks P; Pitt B; Steg PG
    J Am Coll Cardiol; 2023 Nov; 82(19):1842-1851. PubMed ID: 37914514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF.
    Pitt B; Bhatt DL; Szarek M; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Ezekowitz JA; Sun F; Davies MJ; Verma S; Kosiborod MN; Steg PG;
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):879-889. PubMed ID: 37558385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
    Bhatt DL; Szarek M; Steg PG; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Verma S; Lapuerta P; Pitt B;
    N Engl J Med; 2021 Jan; 384(2):117-128. PubMed ID: 33200892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry.
    Becher PM; Savarese G; Benson L; Dahlström U; Karlström P; Mol PGM; Metra M; Bhatt DL; Pitt B; Lund LH
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):343-352. PubMed ID: 36718512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
    Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis.
    Li J; Zhu C; Liang J; Hu J; Liu H; Wang Z; Guan R; Chow J; Yan S; Li L; Ma F; Ma G
    Front Pharmacol; 2023; 14():1303694. PubMed ID: 38044937
    [No Abstract]   [Full Text] [Related]  

  • 12. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus.
    Pitt B; Steg G; Leiter LA; Bhatt DL
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):561-567. PubMed ID: 34750713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes.
    Bantounou MA; Sardellis P; Plascevic J; Awaes-Mahmood R; Kaczmarek J; Black Boada D; Thuemmler R; Philip S
    ESC Heart Fail; 2024 Sep; ():. PubMed ID: 39257196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
    Szarek M; Bhatt DL; Steg PG; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Banks P; Tesfaye E; Ezekowitz JA; Verma S; Pitt B;
    Ann Intern Med; 2021 Aug; 174(8):1065-1072. PubMed ID: 34152828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.
    Pérez MS; Rodríguez-Capitán J; Requena-Ibáñez JA; Santos-Gallego CG; Urooj Zafar M; Escolar G; Mancini D; Mitter S; Lam D; Contreras JP; Fergus I; Atallah-Lajam F; Abascal V; Lala A; Moreno P; Moss N; Lerakis S; Sanz J; Fuster V; Badimon JJ
    Cardiovasc Drugs Ther; 2023 Jun; ():. PubMed ID: 37318685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF.
    Weintraub WS; Kolm P; Dolman S; Alva M; Bhatt DL; Zhang Z
    JACC Heart Fail; 2024 Sep; 12(9):1600-1610. PubMed ID: 38878007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis.
    Tian L; Ai S; Zheng H; Yang H; Zhou M; Tang J; Liu W; Zhao W; Wang Y
    Front Pharmacol; 2022; 13():986186. PubMed ID: 36506550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
    Kotit S
    Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
    Bhatt DL; Szarek M; Pitt B; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Inzucchi SE; Kosiborod MN; Cherney DZI; Dwyer JP; Scirica BM; Bailey CJ; Díaz R; Ray KK; Udell JA; Lopes RD; Lapuerta P; Steg PG;
    N Engl J Med; 2021 Jan; 384(2):129-139. PubMed ID: 33200891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.